Evizia will be at AMP Meeting & Expo – November 21-23, 2024

AMP2024-main-image

Come to BOOTH #525 to meet and learn more about Evizia at the AMP Meeting & Expo held in Vancouver, CA November 21-23, 2024.

AMP is the leading organization in the field of molecular diagnostics, and their annual meeting is widely considered the “premier gathering” of molecular professionals. Featured there is exploring how cutting-edge technology and developments in molecular testing continue to have a major and direct impact on patient care.

We look forward to seeing you there!

Visit their website to learn more about the upcoming AMP Meeting & Expo.

Evizia will be at AACR Annual Meeting – Chicago, April 25-30, 2025

AACR-annual-meeting-logo

Come to BOOTH #3257 to meet and learn more about Evizia at the AACR Annual Meeting to be held in Chicago, IL April 25-30, 2025.

 

Unifying Cancer Science and Medicine: A Continuum of Innovation for Impact

The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.

We look forward to seeing you there!

Visit their website to learn more about the upcoming AMP Meeting & Expo.

Evizia will be at ASHG Annual Meeting – November 6-8, 2024

Logo-for-ASHG-Annual-Meeting-2024
Come to BOOTH #927 to meet and learn more about Evizia at the ASHG Annual Meeting in Denver, CO, November 6-8, 2024.

Join us in Denver where a broad spectrum of topics including new technologies, applications, and research will be showcased to include the most compelling genetics and genomics science of the year.

We look forward to seeing you there!

Visit their website to learn more about the upcoming ASHG Annual Meeting.

Evizia, Inc. awarded one of sixteen grants awarded by Virginia Catalyst

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), announced that it has awarded $3.18 million in grants to four life and bioscience projects in the Commonwealth of Virginia. These grants, which will be met with significant matching funds from partner companies, were awarded through Grant Round 16.

Project:  Optimization and Commercialization of PRECYSE as a Novel Quality Control Solution for Next Generation Sequencing

  • Company: Evizia, Inc. (Charlottesville, VA)
  • Funding amount: $800,000
  • University collaborators: Virginia Commonwealth University and University of Virginia

Read full post on all grants awarded here.

VIPC’s Virginia Venture Partners invests in Evizia to provide tools that identify genomic variations

Company’s tool supports clinicians and researchers working to visualize, analyze and understand the genome in a low-cost, high throughput platform

 

RICHMOND, VIRGINIA, UNITED STATES, September 14, 2022 /EINPresswire.com/ — Virginia Venture Partners, the equity investment program of Virginia Innovation Partnership Corporation (VIPC), today announced an investment in Richmond, Va.-based Evizia. Evizia is building and deploying a breakthrough life science tool which enables high resolution visualization of the genome, assisting researchers working to understand and develop treatments for complex genetic disorders. This investment supports the design and manufacturing of the platform’s new generation and placement with research partners.

Evizia’s tool, PRECYSE, combines nanoimaging, nanoparticle chemistry and proprietary analytics to render quick, automated and accurate data. Its ability to flexibly measure specified regions quickly, accurately, and inexpensively unlocks assessments of sample quality as well identification of genomic variations that underly certain inherited diseases and cancers.

At Evizia, we are committed to developing elegant, inexpensive, and effective tools enabling research scientists by resolving genomic complexity.”

— Sheila Corcoran, evizia, Chief Operating Officer

“At Evizia, we are committed to developing elegant, inexpensive, and effective tools enabling research scientists by resolving genomic complexity. Our team has a deep understanding of the industry, and we are on a mission to provide novel tools for cutting-edge researchers by addressing a significant pain point,” says Sheila Corcoran, Evizia COO and Co-Founder. “We are thrilled to be working alongside scientists and clinicians, developing applications for them. This investment by VIPC’s Virginia Venture Partners supports our growth and we are grateful for the investment.”

PRECYSE flexibly scans and measures DNA, meeting the needs of those who require fast and accurate characterization of genomic structures. The full product platform includes a desktop scanner, reagents and software applications thus automating analysis and delivering output in an easy-to-read format.

“The elucidation of certain structural variants can be a daunting task for genomics researchers,” said Alex Euler, Senior Investment Director, VIPC’s Virginia Venture Partners. “Evizia’s PRECYSE technology provides these researchers with a novel suite of tools that has the potential to revolutionize our understanding of the role that these structural variations play in certain cancers and rare diseases.”

 

About Evizia

Evizia is a start-up life science tools company providing clinicians and researchers with high resolution, automated genomic visualization and measurement. The platform was developed with wide-scale application and adoption in mind, embodied in a desktop scanner as well as companion reagents and software applications. To learn more about Evizia, visit https://eviziadx.com/.

 

About Virginia Venture Partners

Virginia Venture Partners, formerly CIT GAP Funds, is the equity investment program of VIPC that makes seed-stage equity investments in Virginia-based technology, clean energy, and life science companies with a high potential for achieving rapid growth and generating a significant economic return for entrepreneurs, co-investors, and the Commonwealth of Virginia. Since its inception in 2005, Virginia Venture Partners has deployed $32.4 million in capital across more than 250 portfolio companies, including 17 companies in designated Opportunity Zones. Virginia Venture Partners’ investment decisions are guided by the Virginia Venture Partners Investment Advisory Board (IAB). This independent, third-party panel has drawn from the expertise of leading regional entrepreneurs, angel, and strategic investors, and venture capital firms such as New Enterprise Associates, Grotech Ventures, Harbert Venture Partners HIG Ventures, Edison Ventures, In-Q-Tel, Intersouth Partners, SJF Ventures, Carilion Health Systems, Johnson & Johnson, General Electric, and Alpha Natural Resources. For more information, please visit www.virginiaipc.org/vvp.

 

About Virginia Innovation Partnership Corporation (VIPC)

Connecting innovators with opportunities. The nonprofit operations arm of the Virginia Innovation Partnership Authority (VIPA), VIPC is the commercialization and seed stage economic development driver in the Commonwealth that leads funding, infrastructure, and policy initiatives to support Virginia’s innovators, entrepreneurs, startups, and market development strategies. VIPC collaborates with local, regional, state, and federal partners to support the expansion and diversification of Virginia’s economy.